Rapid hereditary breast cancer
Treat breast cancer patients sooner
When it comes to breast cancer treatment, recent studies have shown that a longer time to treatment completion has a negative impact on the overall outcome and survival of patients.1,2
Delivering results in 10–14 days, our rapid breast cancer treatment decision panel is designed to detect 11 genes linked to lifetime breast cancer risk, in alignment with guidelines established by the National Comprehensive Cancer Network (NCCN). Of the 11 genes our panel detects, seven are considered high risk based on NCCN guidelines for breast cancer risk management and treatment. Our panel also includes four moderate-risk genes, allowing clinicians to cast a broader net and reduce the need for subsequent reflex testing.
Rapid hereditary breast cancer test menu
Rapid hereditary breast cancer
Key testing
Advantages
- Includes detection of seven high-risk genes (BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53), which carry a 40%–60% lifetime likelihood of the presence of cancer, and four moderate risk genes (ATM, CHEK2, RAD51C, and RAD51D), which indicate a 20%–40% lifetime likelihood of cancer occurrence.
- Delivers results in 10–14 days, providing clinicians and patients with information to quickly guide treatment decisions.
- Carefully designed to balance clinical utility diagnostic yields and future-proofing that will generate the most impactful genetic testing results for patients with breast cancer.
Highlights
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
References
- Pratt D, Burneikis T, Tu C, Grobmyer S. Time to completion of breast cancer treatment and survival. Ann Surg Oncol. 2021;28(13):8600-8608. doi:10.1245/s10434-021-10116-9.
- Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States [published correction appears in JAMA Oncol. 2016 Sep 1;2(9):1244]. JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508.